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ABSTRACT
Nonclassical human leukocyte antigen (HLA) class I molecule
HLA-G and indoleamine 2,3 dioxygenase (INDO) in humans and
mice, respectively, have been shown to play crucial immuno-
suppressive roles in fetal-maternal tolerance. HLA-G inhibits
natural killer and T cell function by high-affinity interaction with
inhibitory receptors, and INDO acts by depleting the surround-
ing microenvironment of the essential amino acid tryptophan,
thus inhibiting T cell proliferation. We investigated whether
HLA-G expression and INDO function were linked. Working
with antigen-presenting cell (APC) lines and monocytes, we
found that functional inhibition of INDO by 1-methyl-trypto-
phan induced cell surface expression of HLA-G1 by HLA-G1-
negative APCs that were originally cell-surface negative, and
that in reverse, the functional boost of INDO by high concen-
trations of tryptophan induced a complete loss of HLA-G1 cell
surface expression by APCs that were originally cell-surface
HLA-G1-positive. This mechanism was shown to be posttrans-
lational because HLA-G protein cell contents remained unaf-
fected by the treatments used. Furthermore, HLA-G cell surface
expression regulation by INDO seems to relate to INDO func-
tion, but not to tryptophan catabolism itself. Potential implica-
tions in fetal-maternal tolerance are discussed.
embryo, immunology, trophoblast
INTRODUCTION
Human reproduction begins by the uniting of paternal
and maternal gametes, yielding a fetus that is semialloge-
neic with respect to the maternal body in which it will
develop. The immunogenetically different fetus should elic-
it immune responses by the potentially hostile maternal or-
ganism. In fact, pregnancy is a prime example of immu-
notolerance. Although at first glance this maternal tolerance
to the semiallogeneic fetus appears to transgress the clas-
sical rules of immunological responses, when fetal cells are
confronted with maternal immunity, classical immune re-
sponses are subdued or suppressed. Several mechanisms
have been put forth to explain fetal-maternal tolerance,
among which are expression of immunosuppressive non-
classical human leukocyte antigen (HLA) class I molecule
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G (HLA-G) by fetal tissues, and expression of the trypto-
phan-degrading enzyme indoleamine 2,3 dioxygenase
(INDO).
HLA-G is a nonclassical class I HLA whose expression
in nonpathological situations is tissue-restricted to extrav-
illous cytotrophoblast, thymic epithelial cells, and cornea
[1–3]. HLA-G is characterized by a low genomic polymor-
phism of 15 alleles, as well as by 4 membrane-bound and
3 soluble isoforms (HLA-G1 to HLA-G4, and HLA-G5 to
HLA-G7, respectively) that are generated by alternative
splicing of a unique primary transcript [4–8]. HLA-G1 is
the HLA-G isoform that has been investigated the most.
HLA-G1 has a structure similar to that of classical HLA
class I molecules: a heavy chain constituted of three extra-
cellular globular domains noncovalently associated with
beta-2-microglobulin, and a nonameric peptide. Functional
assays demonstrated that both soluble and membrane-
bound HLA-G isoforms were able to inhibit allogeneic pro-
liferation of T cells [9, 10], natural killer (NK) cell cyto-
toxicity [11–15], and antigen-specific T cell cytotoxicity
[16, 17]. HLA-G exerts its inhibitory functions via inter-
action with three inhibitory receptors: LILRB1 (ILT2/
CD85j), LILRB2 (ILT4/CD85d), and KIR2DL4 (CD158d)
[18–21]. LILRB1 is broadly expressed by lymphoid and
myeloid cells, whereas expression of LILRB2 is myeloid-
specific, and expression of KIR2DL4 is restricted primarily
to NK cells. LILRB1 and LILRB2 can interact with clas-
sical HLA class I molecules, but they have a higher affinity
for HLA-G [22], whereas HLA-G is the only known ligand
of KIR2DL4.
HLA-G has been associated with fetal-maternal toler-
ance in humans. HLA-G is expressed as early as the blas-
tocyst stage and is crucial for implantation and early fetal-
maternal tolerance [12, 23]. Indeed, studies performed in
embryos following in vitro fertilization have demonstrated
that clinical pregnancy is obtained only if the growing em-
bryos can produce soluble HLA-G [24]. Furthermore, 1)
recurrent spontaneous abortion and preeclampsia have been
associated with decreased expression/secretion of HLA-G
by fetal tissues [25–28]; and 2) Herpes simplex virus in-
fection, which is linked to spontaneous abortion, has been
shown to block HLA-G intracellular transport to the cell
surface [29]. HLA-G expression by fetal tissues persists
throughout human pregnancy, but its expression by extrav-
illous cytotrophoblast is highest during the first trimester of
development, and might decline thereafter [30].
INDO is an inducible enzyme that catalyzes tryptophan
degradation to formyl-kynurenine, which is then rapidly
metabolized into kynurenine [31]. Until recently, this en-
zyme has been described as part of innate immunity, par-
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ticipating in antimicrobial defense by limiting the growth
of parasites, bacteria, and viruses [32]. By catalyzing tryp-
tophan degradation, INDO depletes the local microenviron-
ment of this essential amino acid form and limits the
growth of these pathogens. Studies by Munn et al. [33]
have shown that INDO plays an important immunosup-
pressive role in mice. The blockade of this enzyme with
the competitive inhibitor 1-methyl-tryptophan (1MT) dur-
ing murine pregnancy results in maternal T cell-mediated
rejection of allogeneic but not syngeneic conceptuses at the
ninth day, but not at the sixth day, of murine pregnancy.
The fetal allograft rejection caused by INDO inhibition is
related to stimulation of innate immunity [34]. It is inter-
esting to note that although INDO inhibition causes abor-
tion in mice, an INDO-knockout mouse has been generated
and does not differ from controls with respect to pregnancy
success, leading to the hypothesis that other immunosup-
pressive mechanisms came into play [35]. The relationship
between pregnancy and INDO activity has not been clearly
established in humans, but some data suggest it can play a
role in fetal-maternal tolerance. Indeed, INDO is expressed
at very low levels in blastocysts [36], but its expression by
placenta increases over time from the first to the third tri-
mester of pregnancy [37]. Using two different antibodies,
INDO expression was evidenced by two independent stud-
ies in syncytiotrophoblast, and one of these antibodies also
stained in invasive extravillous cytotrophoblast [38]. Fur-
thermore, reduced INDO expression levels have been as-
sociated with preeclampsia [39], and INDO transcription
has been found in monocytes from pregnant women but not
in normal controls [40]. Studies in a murine model have
shown that INDO immunosuppressive function can be used
by tumor cells to evade antitumoral immunity [41]. How-
ever, the mechanisms by which INDO exerts its immuno-
regulatory functions seem to extend beyond a mere nutrient
depletion, because tryptophan degradation metabolites also
play a role in the regulation of immune function, probably
through proapoptotic mechanisms. Indeed, it has been
shown that kynurenine and 3-hydroxyanthranilic acid [42]
can cause apoptosis of TH2 cells through a process that
seems to be mediated by oxygen free radicals.
We investigated whether HLA-G expression and INDO
function were linked. We chose to work with monocytes
and monocytic cell lines because these are known to strong-
ly express INDO after recombinant human interferon-g
(IFNG) treatment [43] and because among easily accessible
cells, monocytes are the subset in which HLA-G seems to
be the most likely to be expressed. Indeed, 1) cell surface
HLA-G expression by 4%–10% of monocytes from healthy
donors has been reported, although this is still controver-
sial; 2) HLA-G expression in monocytes could be up-reg-
ulated in vitro by IFNG, interleukin-10, and glucocorti-
coids; and 3) in vivo, HLA-G is expressed by monocytes
that infiltrate tumors and transplants during the course of
autoimmune diseases, and after viral infections (reviewed
in [23]). We found that inhibition of INDO function by
1MT induced HLA-G cell surface expression in monocytes
and antigen-presenting cell (APC) lines. On the other hand,
INDO functional boost in cell surface HLA-G-positive
monocytes and APC lines induced a complete loss of this
HLA-G cell surface expression. INDO-related alterations of
HLA-G cell surface expression occurred without changes
in total HLA-G cellular content, thus arguing in favor of a
posttranslational mechanism. Finally, INDO function, but
not tryptophan catabolism, seems to be responsible for
HLA-G cell surface expression regulation.
MATERIALS AND METHODS
Cells and Cell Lines
The following human cell lines were used: U937 histiocytic lymphoma
(American Type Culture Collection, Manassas, VA), THP-1 acute mono-
cytic leukemia (American Type Culture Collection), HLA-G1 and HLA-
G5-transfected melanoma lines M8-HLA-G1 and M8-HLA-G5 [44], nat-
urally HLA-G-expressing melanoma line FON, and HLA-G-expressing
choriocarcinoma line JEG-3 (American Type Culture Collection). HLA-
G-positive and HLA-G-negative U937 and THP-1 cells arose from bulk
culture and were sorted according to cell surface HLA-G expression using
anti-HLA-G-coated magnetic beads (Dynal Biotech France, Compiegne,
France). Differentiation of THP-1 cells into macrophages was achieved by
treatment with phorbol ester miristate during 72 h as previously described
[45]. For purification, monocytes and peripheral blood mononuclear cells
were first isolated on Ficoll Hypaque (Sigma, St. Louis, MO), and mono-
cytes were separated after adherence on plastic plates.
Cell Culture and Treatments
All cells were maintained in RPMI 1640 medium supplemented with
10% heat-inactivated fetal calf serum, 2 mM L-glutamine, and 1 mg/ml
gentamicin and fungizone (Sigma). When indicated, cells were treated
with 500 IU IFNG (Sigma), 10 mg/ml LPS (Sigma), 1 mM tryptophan
(Sigma), 1 mM 1MT, 1 mM kynurenine (Sigma), or a combination of
these. Treatment of APCs with IFNG boosts INDO expression as well as
INDO function, and even more so if IFNG is combined with lipopolysac-
charide (LPS) treatment [43, 46, 47]. Similarly, increasing tryptophan con-
centrations in the culture medium increases INDO function and production
of kynurenine [48]. 1MT is a competitive inhibitor of tryptophan with
respect to INDO function and blocks this metabolic pathway [49].
Antibodies, Flow Cytometry, and Immunohistochemistry
For flow cytometry and immunohistochemistry we used the following
mouse monoclonal antibodies: biotinylated anti-pan HLA class I W6/32
(Leinco Technologies, St Louis, MO), anti-HLA-A,-B,-C,-E TP25.99 (a
kind gift from Dr. S. Ferrone, Roswell Park Cancer Institute, Buffalo, NY),
anti-HLA-G1/HLA-G5 MEMG/09 (Exbio, Praha, Czech Republic), anti-
pan HLA-G 4H84 (a kind gift from Dr. McMaster, University of California
at San Francisco, San Francisco, CA), anti-HLA-G5,-G6 5A6G7B12 [50],
anti-INDO (Chemicon, Temecula, CA), and anti-beta-2-microglobulin
(Boehringer-Mannheim, Mannheim, Germany) in combination with sec-
ondary antibodies phycoerythrin-conjugated goat anti-mouse immuno-
globulin G (IgG; Immunotech, Marseille, France) and horseradish perox-
idase (HRP)-conjugated goat anti-mouse IgG (DAKO, Hamburg, Germa-
ny). For flow cytometry analyses, Fc receptors were blocked by a 30-min
incubation in 25% human serum, and isotypic controls were systematically
included. Analyses were carried on an EPICS XL cytometer (Beckman
Coulter, Krefeld, Germany) using the Expo32 software (Beckman Coul-
ter). Analysis of HLA-G and INDO expression by immunohistochemistry
was carried out on cytospins (Labonord, Templemars, France). The meth-
odology for performing HLA-G immunohistochemistry is described else-
where [51]. The positive control was M8-HLA-G5 cells. Immunohisto-
chemistry for INDO was performed on cytospin slides using Ultratech
HRP (Immunotech). Slides were rehydrated for 5 min in PBS containing
0.1% Triton X-100. Nonspecific binding was prevented by applying pro-
tein blocking agent for 10 min before staining with anti-INDO monoclonal
antibody (mAb) at a dilution of 1:150 for 30 min at room temperature.
An isotype-matched antibody was used under similar conditions to control
nonspecific staining. Cell immunostaining was evaluated on tissues cells
using the DAKO EnVision 1 System, peroxidase (AEC; DAKO).
Enzyme-Linked Immunosorbent Assay
The presence of soluble HLA-G was evaluated using two different
ELISA methodologies specific for either secreted HLA-G5 and shed HLA-
G1, or for HLA-G5 only. An ELISA specific for HLA-G5 and shed HLA-
G1 used anti-HLA-G MEM-G/09 as the capture antibody and anti-beta-2-
microglobulin as the secondary antibody, and has been described else-
where [50]. An ELISA specific for HLA-G5 used anti-HLA-G5
5A6G7B12 mAb as the capture antibody, biotinylated anti-pan class I W6/
32 mAb as the secondary antibody, and streptavidin-HRP for revelation.
The methodology for this ELISA has been published elsewhere [50].
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FIG. 1. HLA-G expression by cell surface
HLA-G1-positive THP-1-HLA-G11 cells
and monocytes-HLA-G11, and by cell sur-
face HLA-G1-negative THP-1-HLA-G12
cells and monocytes-HLA-G12 cells. A)
Cell surface of HLA-G1 in THP-1-HLA-
G12 and THP-1-HLA-G11 cells by flow
cytometry using anti-HLA-G1 MEM-G/09
mAb (plain lines) or isotypic control mAb
(dotted lines). B) Expression of all HLA-G
isoforms in THP-1-HLA-G12 or THP-1-
HLA-G11 cells by immunohistochemistry
using anti-pan-HLA-G mAb 4H84 (red
staining). C) Cell surface of HLA-G1 in
monocytes-HLA-G12 and monocytes-HLA-
G11 cells by flow cytometry using anti-
HLA-G1 MEM-G/09 mAb (dark lines) or
isotypic control mAb (dotted lines). D) Ex-
pression of all HLA-G isoforms in mono-
cytes-HLA-G12 and monocytes-HLA-G11
by immunohistochemistry using anti-pan-
HLA-G mAb 4H84 (red staining). Original
magnification 310.
INDO Activity Assay
INDO activity was assessed using the method described by Yoshida et
al. [52]. Briefly, frozen cell pellets were diluted in antiprotease buffer
(Roche Molecular Diagnostics, Mannheim, Germany). Extracts were cen-
trifuged at 13 000 3 g for 10 min at 48C and added to the assay reagent
(100 mM potassium phosphate buffer pH 6.5, 40 mM ascorbate, 20 pM
methylene blue, 200 mg/ml catalase, and 800 mM L-tryptophan). After 30
min of incubation at 378C, the reaction was stopped by adding 200 ml of
30% (w/v) trichloroacetic acid. The solution was boiled for an additional
10 min and centrifuged at 2500 3 g for 10 min. Kynurenine in the su-
pernatant was measured in a high-performance liquid chromatography sys-
tem with a Waters C18 column (4.5 mm 3 15 cm). The mobile phase was
15 mM acetic acid-sodium acetate (pH 4.0) containing 27 ml/L acetoni-
trile, and kynurenine was detected by absorbance at 360 nm. One unit of
the enzyme activity was defined as the amount that produced 1 nmol of
kynurenine per hour. Protein was determined using the Quick Start Brad-
ford Protein Assay Kit (Bio-Rad, Mississauga, ON, Canada) with BSA as
the standard.
Western Blotting
Frozen cell pellets were diluted in antiprotease buffer (Roche). Extracts
were centrifuged at 13 000 3 g for 10 min at 48C, and 10 mg of the total
protein was run on 12% SDS-PAGE. Proteins were then transferred to a
nitrocellulose membrane (Amersham Biosciences, Freiburg, Germany) by
a Mini Trans-Blot Cell (Bio-Rad). Blots were incubated with either anti-
INDO mAb (USBiological, Euromedex, Souffelweyersheim, France), or
4H84 antibody, which recognizes all isoforms of HLA-G, or 5A6G7B12,
which recognizes secreted HLA-G5 and HLA-G6, or anti-beta-actin mAb
(Abcam, Cambridge, United Kingdom). HRP-conjugated secondary anti-
body (Amersham Biosciences) was used, and the bands were visualized
using an ECL1 Plus Western blotting detection system (Amersham Bio-
sciences).
Statistical Analyses
To determine the significance of HLA-G expression differences before
and after treatment, percentages of HLA-G-positive cells were compared
before and after treatment with a positivity cutoff set using isotypic con-
trols. Experiments performed more than six times were analyzed, and sig-
nificance was assessed using the Fisher exact test. Differences were con-
sidered significant when P , 0.05.
RESULTS
Experimental Model: Unmodified HLA-G-Positive
and HLA-G-Negative U937 and THP-1 APC Line;
HLA-G-Positive and HLA-G-Negative Monocytes
To study the relationship between INDO and HLA-G,
we searched for a cellular model in which HLA-G and
INDO could be naturally expressed. Screening for HLA-G
expression in APC lines revealed that monocytic U937 and
THP-1 lines could express cell surface HLA-G in culture,
in the absence of any treatment. Of note, THP-1 and U937
cell lines constitutively express INDO, but with a low basal
activity (less than 12 nmol kynurenine per milligram of
protein per hour; data not shown) and have been shown to
express a low basal transcription level of HLA-G that can
be up-regulated upon cytokine treatment [53]. U937 and
THP-1 cultures were therefore divided into cell surface
HLA-G1-negative U937 and THP-1 lines (U937-HLA-G12
and THP-1-HLA-G12), and cell surface HLA-G1-positive
U937 and THP-1 lines (U937-HLA-G11 and THP-1-HLA-
G11). Similarly, when screening for cell surface HLA-G-
positive monocytes, we could identify a donor in which,
exceptionally, all monocytes expressed cell surface HLA-
G1 (thereafter named monocytes-HLA-G11). U937-HLA-
G12 and U937-HLA-G11, THP-1-HLA-G12 and THP-1-
HLA-G11, and monocytes-HLA-G12 and monocytes-HLA-
G11 constituted our working experimental model. Expres-
sion of HLA-G1 for THP-1 cells and monocytes is
illustrated in Figure 1.
1MT (INDO Functional Inhibitor) Induces Cell-Surface
Expression by HLA-G-Negative APC Lines
and Monocytes
To investigate the role of INDO in the expression reg-
ulation of HLA-G, we treated U937-HLA-G12 and THP-1-
HLA-G12 lines, macrophage-differentiated THP-1-HLA-
G12 (MF-THP-1-HLA-G12), and monocytes with trypto-
phan, 1MT, IFNG plus LPS, IFNG plus LPS plus trypto-
phan, or IFNG plus LPS plus 1MT. The effectiveness of
the different treatments with respect to INDO function was
assessed by kynurenine titration in culture supernatants and
expression of cell-surface HLA-G1 by the treated cells (24
h for cell lines, and 48 h for monocytes) was investigated
by flow cytometry. Cell surface expression of HLA-G and
HLA-A,-B,-C,-E was measured using MEM-G/09, and
TP25.99 mAbs, respectively, in monocytes, THP-1 cells,
and macrophage-differentiated THP-1 cells (MF-THP-1)
after no treatment (N.T.), or treatment with 1MT, IFNG plus
LPS (IFNG1LPS), or IFNG plus LPS plus 1MT
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FIG. 2. 1MT induces cell-surface HLA-
G1 up-regulation in APC lines and mono-
cytes. Cell surface HLA-G1-negative
monocytes, THP-1 cells, and macrophage-
differentiated THP-1 cells (MF-THP-1)
were untreated (N.T.), or treated as de-
tailed in Materials and Methods with tryp-
tophan (Trp), 1MT, IFNG1LPS,
IFNG1LPS1Trp, or IFNG1LPS11MT, as
indicated. Histograms: HLA-G1 cell sur-
face expression was evaluated by flow cy-
tometry after 24 h for THP-1 cells and
monocyte-differentiated THP-1 cells, and
after 48 h for monocytes. Dark lines,
MEM-G/09 staining; dotted lines, isotypic
control. Arrows point to increased cell sur-
face expression of HLA-G1.
TABLE 1. Up-regulation of cell-surface expression of HLA-G, but not other HLA Class I molecules after treatment with 1-Methyl-Tryptophan.a
Cellsb Antigen
Treatment
No treatment 1MT IFNG1LPS IFNG1LPS11MT
Monocytes
(N 5 6)
HLA-G
HLA-A-B-C-E
3.50 6 1.50
89.00 6 5.00
5.5 6 2.1
68.0 6 2.00
3.40 6 1.30
81.00 6 18.00
6.00 6 2.10
67.00 6 14.00
THP-1
(N 5 7)
HLA-G
HLA-A-B-C-E
0.83 6 0.10
4.50 6 3.20
2.75 6 0.90
4.30 6 1.00
1.10 6 0.17
4.55 6 3.60
4.10 6 2.20
5.20 6 2.10
MF-THP-1
(N 5 5)
HLA-G
HLA-A-B-C-E
1.75 6 0.20
25.30 6 4.00
2.2 6 0.40
26.00 6 2.00
2.58 6 0.67
26.6 6 4.00
13.00 6 8.10
25.5 6 2.00
a Results are expressed as the mean fluorescence intensity 6 SEM of the total cell population.
b N 5 number of independent experiments analyzed.
(IFNG1LPS11MT). Results obtained for one representa-
tive experiment out of seven for THP-1-HLA-G12, out of
five for MF-THP-1-HLA-G12 cells, and out of six for
monocytes-HLA-G12 are shown Figure 2. Results obtained
for six experiments with U937-HLA-G12 cells were iden-
tical to those obtained for THP-1-HLA-G12 and are not
shown. THP-1-HLA-G12 cells and U937-HLA-G12 cells
significantly up-regulated HLA-G1 cell surface expression
after treatment with 1MT alone or in combination with
IFNG1LPS, whereas treatment with tryptophan alone, or
IFNG1LPS, or the two combined, had no effect. Similarly,
HLA-G1 cell surface expression was significantly up-reg-
ulated in monocytes after treatment with
IFNG1LPS11MT, but not after any other treatment. Thus
functional inhibition of INDO with 1MT induced HLA-G1
cell surface expression in APC lines and monocytes. This
effect seemed to be specific for HLA-G, because none of
the treatments used on any of the cells described had any
effect on other HLA class I cell-surface expression, as
shown by concomitant staining with TP25.99, an antibody
specific for HLA-A,-B,-C,-E, but not for HLA-G (Table 1).
HLA-G Cell-Surface Expression Up-Regulation on APC
by 1MT Is Transitory
It has been reported that HLA-G cell surface up-regu-
lation on U937 cells following IFNG treatment was tran-
scriptional and transitory, and that such an induced cell-
surface expression lasted less than 48 h [54]. Even though
in our system IFNG alone or used in combination with LPS
had no effect on HLA-G cell surface expression after 24 h,
we investigated whether INDO inhibition-dependent HLA-G
cell surface up-regulation was permanent or transitory. To
address this question, kinetic studies were set up using cell
surface HLA-G-negative monocytes, and U937-HLA-G12
and THP-1-HLA-G12 cells. These cells were treated 1)
once with IFNG1LPS or IFNG1LPS11MT, for 12, 24, 48,
and 72 h; or 2) every 24 h with IFNG1LPS or
IFNG1LPS11MT for 72 h. In this latter case, LPS, IFNG,
and 1MT were added to the existing culture medium. At
each time point, HLA-G1 cell surface expression was mea-
sured by flow cytometry, and release of shed HLA-G1 or
secreted HLA-G5 (or both) in the culture medium was an-
alyzed by ELISA. The obtained results from four experi-
ments show that treatment of either cell type with
IFNG1LPS11MT induced HLA-G cell surface expression
as early as 12 h for THP-1-HLA-G12 cells, and 24 h for
U937-HLA-G12 cells. This cell surface up-regulation was
indeed transitory, and 72 h after treatment, all cells had lost
HLA-G1 cell surface expression. However, cell surface
HLA-G1 could still be detected at 72 h after renewed
IFNG1LPS11MT treatment every 24 h, even if it was at
lower levels than those detected after 12 or 24 h of treat-
ment (Fig. 3). The presence of HLA-G1/HLA-G5 was not
detected at either time point after one treatment, probably
due to assay sensitivity. However, renewed treatment with
IFNG1LPS11MT but not with IFNG1LPS allowed the
detection of shed HLA-G1 (35 ng/ml), but not of HLA-G5
in the culture supernatants, ruling out the eventuality of
flow cytometry artifacts (data not shown).
HLA-G Cell-Surface Expression Up-Regulation on APCs
by 1MT Is Posttranslational
To gain insight into the mechanism involved in cell-sur-
face HLA-G up-regulation, we investigated whether it was
a transcriptional, posttranscriptional, translational, or post-
translational mechanism. Cell surface HLA-G1-negative
THP-1 cells were stimulated once with IFNG1LPS or
IFNG1LPS11MT for 12 h, corresponding to maximal cell
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FIG. 3. HLA-G1 cell surface up-regula-
tion by 1MT is transitory. HLA-G1 cell sur-
face expression in THP-1-HLA-G12 and
U937-HLA-G12 cells after treatment with
IFNG1LPS (dotted lines) or with
IFNG1LPS11MT (dark lines) were investi-
gated after 12, 24, 48, or 72 h, or after
three 24-h treatments. The isotypic control
is the shaded histogram. Arrows point to
increased HLA-G1 cell surface expression.
FIG. 4. HLA-G protein expression in
THP-1 cells after treatment with 1MT us-
ing three different anti-HLA-G antibodies.
HLA-G expression was analyzed in THP-1
cells after 12 h of no treatment (N.T.),
IFNG1LPS treatment, or IFNG1LPS11MT
treatment. A) HLA-G1 cell surface expres-
sion and intracellular content using MEM-
G/09 mAb. Shaded histograms are the iso-
typic control. B) HLA-G total cellular con-
tent (all HLA-G isoforms) with MEM-G/01
mAb (JEG-3 was used as a positive HLA-
G-expressing control and beta-actin was
used as the internal control). C) Total HLA-
G expression by immunohistochemistry
using 4H84 mAb (red staining). Original
magnification 310.
surface HLA-G1 up-regulation. At this time point, analyses
were carried as follows: 1) cell surface expression of HLA-
G1 and total HLA-G1 contents were investigated by flow
cytometry and intracellular flow cytometry, respectively,
and 2) total HLA-G cellular contents were evaluated by
Western blotting and immunohistochemistry.
Intracellular flow cytometry, immunohistochemistry, and
Western blot analyses first revealed that even though HLA-G
could not be detected at the cell surface, THP-1-HLA-G12
cells, even untreated, expressed a basal level of HLA-G1 pro-
tein. Furthermore, total HLA-G cellular contents were iden-
tical following either treatment: No differences were observed
between cells that were untreated, treated with IFNG1LPS,
and treated with IFNG1LPS11MT. Western blot analyses
also revealed that HLA-G1 was the sole HLA-G isoform de-
tected (see Fig. 4, which is representative of three such ex-
periments).
Thus, these experiments showed that treatment of HLA-
G1-expressing, but cell surface HLA-G1-negative APC
lines with IFNG1LPS11MT induced a fast but transitory
HLA-G1 cell surface expression that occurred without
HLA-G cellular content increase, hence, via a posttransla-
tional mechanism. Renewed treatment with IFNG1LPS1
1MT was the only treatment that allowed HLA-G1 cell sur-
face expression to last.
Tryptophan Induces Loss of HLA-G1 Cell Surface
Expression in HLA-G1-Positive APC Lines and Monocytes
1MT is a competitive inhibitor of tryptophan degrada-
tion by INDO. Because 1MT induced up-regulation of cell
surface HLA-G1 expression in HLA-G-negative APC lines
and monocytes, we investigated whether the reverse was
true (i.e., whether increased concentrations of tryptophan,
mimicking increased INDO function, induced down-regu-
lation of HLA-G1 cell surface expression in HLA-G1-pos-
itive APC lines and monocytes).
As can be seen in Figure 5, a 24-h treatment of U937-
HLA-G11 (n 5 3) and THP-1-HLA-G11 (n 5 3) lines and
cell surface HLA-G1-positive monocytes-HLA-G11 (n 5
1) with IFNG1LPS1tryptophan induced a complete loss
of HLA-G1 cell surface expression, whereas IFNG and LPS
treatment alone or IFNG1LPS11MT had no effect (Fig.
5). Concomitant staining with HLA-A,-B,-C,-E, but not
with HLA-G-specific antibody showed that the treatments
used had no effects on the expression levels of HLA class
I molecules other than HLA-G1 (data not shown).
HLA-G1 Cell Surface Up-Regulation by 1MT
Is Not a Mechanism Restricted to APC and Is Active
in Tumor Lines
We wanted to determine whether up-regulation of cell-
surface HLA-G1 expression was a mechanism that was re-
stricted to APCs. Because INDO in mice and HLA-G in
humans were shown to be involved in escaping antitumor
immunity [41, 55], we treated the HLA-G1-expressing hu-
man melanoma line FON with 1MT for 72 h. This treat-
ment induced a cell surface HLA-G1 up-regulation in the
FON line, as had been observed for APC lines and mono-
cytes (Fig. 6).
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FIG. 5. Tryptophan induces loss of HLA-
G1 cell surface expression in HLA-G1-
positive APC lines and monocytes. THP-1-
HLA-G11 cells and monocytes-HLA-G11
were untreated (N.T.) or treated as detailed
in Materials and Methods with tryptophan
(Trp), 1MT, IFNG1LPS, IFNG1LPS1Trp,
or IFNG1LPS11MT, as indicated. Dotted
lines represent the isotypic control, plain
lines are HLA-G1 cell surface expression
levels, and arrows point to down-regula-
tion of cell surface HLA-G1 expression.
FIG. 6. 1MT induces HLA-G1 cell surface up-regulation in a tumor line.
HLA-G1 cell surface expression in the HLA-G1-positive FON melanoma
line after 72 h of no treatment (N.T.) or treatment with 1 mM 1MT
(11MT). Dotted lines are the isotypic control, plain lines are HLA-G1 cell
surface expression.
DISCUSSION
INDO and nonclassical HLA class I HLA-G are two
molecules involved in immune suppression, and both are
involved in the protection of fetal tissues against destruc-
tion by the mother’s immune system [23, 33, 56]. The most
widely accepted hypothesis for INDO immunosuppressive
function is that it acts by depleting the microenvironment
that surrounds the cells of the essential amino acid trypto-
phan, thus inhibiting proliferation of immune cells, among
others. HLA-G is the main HLA class I molecule expressed
at the surface of extravillous cytotrophoblast at the fetal-
maternal interface. HLA-G inhibits the function of immune
cells (NK cells, T cells, and APCs) by high-affinity inter-
action with inhibitory receptors LILRB1 (CD85j/ILT2),
LILRB2 (CD85d, ILT4), and KIR2DL4 (CD158d) [23]. We
investigated whether these immunosuppressive mechanisms
were linked, and we focused our efforts on the effects of
INDO function on HLA-G expression.
Working with cell lines and monocytes that did or did
not express cell surface HLA-G, we found that INDO func-
tion and HLA-G expression were indeed linked. Our results
show that INDO function seems to prevent HLA-G cell
surface expression. Indeed, cell surface HLA-G-negative
APC lines and monocytes expressed cell surface HLA-G1
when treated with 1MT, a competitive inhibitor of INDO
function. In the reverse experiments, cell surface HLA-G1-
positive APC lines and monocytes lost HLA-G1 cell sur-
face expression after treatment with tryptophan. Thus,
HLA-G cell surface expression was up-regulated by INDO
functional inhibition, and down-regulated by INDO func-
tional boost. HLA-G cell surface expression up-regulation
by INDO inhibition is fast and transient: HLA-G cell-sur-
face expression was maximal 12–24 h after 1MT treatment,
and unless this treatment is renewed, cell surface HLA-G
is no longer detectable after 72 h. This might indicate that
1) 1MT is degraded during this period and no longer pro-
motes HLA-G cell surface expression, or that 2) it is not
INDO functional levels per se, but rather sudden stress-like
variations in INDO functional levels that trigger HLA-G
cell surface expression changes. Of note, cell surface HLA-G
levels after three 24-h treatments were much lower than
those detected 12–24 h after the first treatment. This would
argue in favor of the latter hypothesis of INDO-related
stress-inducing HLA-G cell surface expression regulation.
Cell lines and monocytes responded to treatment with dif-
ferent kinetics: Maximal HLA-G1 cell surface up-regula-
tion occurred at 12 h after 1MT treatment for THP-1-HLA-
G12 cells, at 24 h for U937-HLA-G12 cells, and between
24 and 48 h for monocytes. The reasons for these differ-
ences are not known, but the fast kinetics of THP-1-HLA-
G12 response led us to reason that HLA-G1 cell surface
up-regulation might have little to do with transcription up-
regulation, and more with posttranscriptional mechanisms.
Thus, HLA-G protein production after treatment with 1MT
was investigated. As had been reasoned, cell surface HLA-G
up-regulation did not relate to HLA-G cellular content that
was unaffected by any treatment, and was stable throughout
the kinetics study. These experiments showed that inhibi-
tion of INDO induces a cell surface expression of HLA-G
that is a posttranslational mechanism.
The reverse experiments were performed and it was
found that increased tryptophan concentrations induced a
down-regulation of cell surface HLA-G1 levels in cell sur-
face HLA-G1-positive APC lines and monocytes. In the
experiments with 1MT described above, kinetic studies
showed that HLA-G cell surface down-regulation by INDO
functional boost was fast but temporary, complete after 12–
24 h of treatment, and finished by 72 h. Protein expression
studies could not be carried out, but given the fast and
transitory kinetics of HLA-G modulation by INDO func-
tional boost, it is likely that the mechanism involved is once
again posttranslational.
The precise nature of the mechanisms involved in
INDO-dependent HLA-G cell surface expression regulation
is unknown. However, it is clear that the mechanisms de-
scribed here do not fit the tryptophan-depletion immuno-
suppressive theory, and that tryptophan degradation or its
lack thereof is not involved. The tryptophan-depletion the-
ory proposes that tryptophan concentrations affect the pro-
liferation rate of cells and pathogens. Accordingly, in-
creased INDO function would deplete the surrounding mi-
croenvironment of tryptophan and have immunosuppres-
sive effects. In our systems, treatment of APCs with IFNG
plus LPS induced an increased INDO function, and there-
fore tryptophan depletion. However, this had no effect on
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HLA-G1 cell surface expression modulation in HLA-G1-
positive or HLA-G1-negative APCs. Furthermore, addition
of tryptophan or addition of 1MT both led to a nondeple-
tion of tryptophan in the medium. Yet these two treatments
had opposite effects, both in terms of INDO activity and
HLA-G1 cell surface expression regulation. Thus, it is
INDO activity that seems to be responsible for HLA-G1
cell surface expression regulation, not tryptophan concen-
trations. Tryptophan could also affect HLA-G expression,
not because of its availability/unavailability, but possibly
because of some tryptophan metabolite, either present or
not present, in the INDO degradation pathway. Because it
was established that INDO function rather than tryptophan
concentrations were involved in cell surface HLA-G1 ex-
pression regulation, we first thought that some product of
tryptophan degradation would be responsible for the ob-
served effect. In the tryptophan degradation pathway, it is
INDO that is limiting. Thus, supplying kynurenine is a
more efficient way of generating tryptophan degradation
products than adding tryptophan at an equivalent concen-
tration. We treated APC lines with kynurenine to generate
tryptophan degradation products and to investigate whether
one of these would be responsible for HLA-G1 cell surface
expression modulation. This treatment had no affect, and
no modification of HLA-G1 cell-surface expression was ob-
served. This ruled out involvement of the tryptophan deg-
radation pathway in INDO-driven HLA-G cell surface ex-
pression regulation.
INDO is an enzyme that breaks the indoleamine ring of
tryptophan, leading to kynurenine production. This is an
oxidative reaction that consumes oxygen free radicals [57].
Because INDO uses superoxide anion as its substrate and
cofactor, it is considered that INDO functions as an anti-
oxidant [58]. Because HLA-G cell surface expression reg-
ulation is related to INDO function, but not to tryptophan
degradation metabolism, one can hypothesize that it is the
INDO antioxidative function that is involved in HLA-G1
cell surface expression modulation. As a matter of fact,
oxygen free radicals have been shown to play a role in the
regulation of HLA expression and immune reactions [59].
Based on in vivo expression studies and in vitro func-
tional studies, INDO in mice [41] and HLA-G in humans
[44, 55], respectively, are suspected to play a role in the
protection of tumors against antitumoral immunity. Treat-
ment of HLA-G-expressing FON melanoma lines with
1MT leads to HLA-G cell surface up-regulation. This in-
dicates that this mechanism is not restricted to APCs, but
that HLA-G and INDO expression might co-contribute to
tumor immune escape mechanisms.
It is our belief that HLA-G expression regulation by
INDO function in APCs might be a novel mechanism of
immune regulation. It not clear whether this mechanism
plays a role in HLA-G expression regulation during preg-
nancy. However, one can hypothesize that HLA-G and
INDO, which have been associated with fetal-maternal tol-
erance in humans and in mice, respectively, act coopera-
tively. Indeed, it is interesting to consider that although
INDO functional inhibition in mice leads to abortion, an
INDO knockout mouse was generated [35], indicating that
INDO is not the key to murine fetal-maternal tolerance by
itself. Cell surface expression modulation of HLA-G in hu-
mans or of its functional homologue in mice might com-
pensate INDO functional fluctuations, the reverse being still
unknown. Because HLA-G is crucial to early human preg-
nancy [12, 24], INDO is expressed primarily after the 14th
week of pregnancy in humans [37], and INDO seems to be
involved in later pregnancy in mice [33], it is conceivable
that HLA-G and INDO could have two complementary,
linked, but not redundant roles in maintenance of the ma-
ternal tolerance toward the fetus.
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